Fed. Circ. Kills Mylan's Prilosec Antitrust Claims
The Federal Circuit on Tuesday rejected Mylan Laboratories Inc.'s bid to revive allegations that AstraZeneca AB violated antitrust law by filing sham patent infringement suits to protect its heartburn drug Prilosec....To view the full article, register now.
Already a subscriber? Click here to view full article